Radiotherapy in Geriatric Head and Neck Cancer Patients

radyasyon_onkolojisi_102

Gülhan GÜLER AVCIa , Evrim METCALFEb
aTokat Gaziosmanpaşa University Faculty of Medicine, Department of Radiation Oncology, Tokat, Türkiye
bİstanbul Medipol University Faculty of Medicine, Department of Radiation Oncology, İstanbul, Türkiye

Güler Avcı G, Metcalfe E. Radiotherapy in geriatric head and neck cancer patients. In: Metcalfe E, ed. Radiotherapy and Current Developments in Geriatric Cancers. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.9-14.

ABSTRACT

Treatment of elderly and frail head and neck cancer patients warrant special consideration of patient requests, life expectancy, acceptable morbidity, comorbidities, functional status, and nutrition. An assessment of the patient’s fitness and frailty beyond chronological age is extremely important in the treatment decision. We can make this evaluation by incorporating comprehensive geriatric examination and G8 tests into our daily practice. In current studies on head and neck cancer patients, over the age of 70 is the exclusion criteria, however, more guiding studies with the elderly patients are needed in order to obtain a consensus on the treatment of elderly and fragile patients. In this section, current approaches and developments in radiotherapy of geriatric head and neck cancer patients are presented in the light of the literature.

Keywords: Head and neck neoplasms; geriatrics; radiotherapy

Referanslar

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002;55:74-108. [Crossref]  [PubMed]
  2. Sikora AG. The changing demographics of head and neck squamous cell carcinoma in the United States. Laryngoscope 2004;114:1915-23. [Crossref]  [PubMed]
  3. Coca-Pelaz A, Halmos GB, Strojan P, de Bree R, Bossi P, Bradford CR, et al. The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. Head Neck. 2019;41:2410-29. [Crossref]  [PubMed]
  4. Rim CH, Yoon WS, Lee JA, Yang DS, Lee NK, Park YJ, et al. Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients. Strahlenther Onkol. 2018;194:894-903. [Crossref]  [PubMed]
  5. Mady LJ, Baddour K, Hodges JC, Magaña LC, Schwarzbach HL, Borrebach JD, et al. The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm. Oral Oncol. 2022;126:105766. [Crossref]  [PubMed]  [PMC]
  6. Dickstein DR, Lehrer EJ, Hsieh K, Hotca A, Jones BM, Powers A, et al. Management of Older Adults with Locally Advanced Head and Neck Cancer. Cancers (Basel). 2022;14(11):2809. [Crossref]  [PubMed]  [PMC]
  7. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595-603. [Crossref]  [PubMed]  [PMC]
  8. VanderWalde NA, Deal AM, Comitz E, Stravers L, Muss H, Reeve BB, et al. Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients with Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017;98:850-7. [Crossref]  [PubMed]
  9. Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, et al. G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy. BMC Cancer. 2015;15:875. [Crossref]  [PubMed]  [PMC]
  10. Neve M, Jameson MB, Govender S, Hartopeanu C. Impact of geriatric assessment on the management of older adults with head and neck cancer: A pilot study. J Geriatr Oncol. 2016;7:457-62. [Crossref]  [PubMed]
  11. Bossi P, Esposito A, Vecchio S, Nicolai P, Tarsitano A, Mirabile A, et al. Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study. In Proceedings of the European Society of Medical Oncology, Lugano, Switzerland, 16-21 September 2021. [Crossref]
  12. Corry J, Peters LJ, Costa ID, Milner AD, Fawns H, Rischin D, et al. The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol. 2005;77(2):137-42. [Crossref]  [PubMed]
  13. Ferro M, Macchia G, Re A, Buwenge M, Ferro M, Boccardi M, et al. Advanced head and neck cancer in older adults: Results of a short course accelerated radiotherapy trial. J Geriatr Oncol. 2021;12(3):441-5. [Crossref]  [PubMed]
  14. Chen AM, Vaughan A, Narayan S, Vijayakumar S. Palliative radiation therapy for head and neck cancer: toward an optimal fractionation scheme. Head Neck. 2008; 30(12):1586-91. [Crossref]  [PubMed]
  15. Lok BH, Jiang G, Gutiontov S, Lanning RM, Sridhara S, Sherman EJ, et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol. 2015;51:957-62. [Crossref]  [PubMed]  [PMC]
  16. Benhmida S, Sun R, Gherga E, Hammoud Y, Rouvier J, Mauvais O, et al. Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases. Cancer Radiother. 2020;24(8):812-9. [Crossref]  [PubMed]
  17. Thomson DJ, Palma D, Guckenberger M, Balermpas P, Beitler JJ, Blanchard P, et al. Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy during the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. Int J Radiat Oncol Biol Phys. 2020;107:618-27. [Crossref]  [PubMed]  [PMC]
  18. Bonomo P, Desideri I, Loi M, Lo Russo M, Olmetto E, Maragna V, et al. Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy? Oral Oncol. 2017;74:142-7. [Crossref]  [PubMed]
  19. Al-mamgani A, Tans L, Van rooij PH, Noever I, Baatenburg de Jong RJ, Levendag PC. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment. Acta Oncol. 2009;48(4):562-70. [Crossref]  [PubMed]
  20. Desideri I, Becherini C, Belgioia L, Merlotti A, Ciccone LP, Franzese C, et al. Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: A systematic review. Oral Oncol. 2021;119:105355. [Crossref]  [PubMed]
  21. Haehl E, Rühle A, David H, Kalckreuth T, Sprave T, Stoian R, et al. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol. 2020;15(1):31. [Crossref]  [PubMed]  [PMC]
  22. Ermiş E, Teo M, Dyker KE, Fosker C, Sen M, Prestwich RJ. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions. Radiat Oncol. 2015;10:203. [Crossref]  [PubMed]  [PMC]
  23. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group MNC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14. [Crossref]  [PubMed]
  24. VanderWalde NA, Meyer AM, Deal AM, Layton JB, Liu H, Carpenter WR, et al. Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys. 2014;89(1):30 -7. [Crossref]  [PubMed]
  25. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-78. [Crossref]  [PubMed]
  26. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-8. [Crossref]  [PubMed]
  27. De Felice F, Vetrone L, Bulzonetti N, Caiazzo R, Marampon F, Musio D, et al. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma. Med Oncol. 2019;36(8):68. [Crossref]  [PubMed]
  28. Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2023;34(1):101-10. [Crossref]  [PubMed]